Dr. Hönle (HNL) Q1 2025 earnings summary

Executive summary

• Revenue declined 10.0% year-over-year to €21.4 million due to postponed orders and discontinued unprofitable product areas.

• EBITDA improved 69.4% to €1.0 million, reflecting cost-cutting and restructuring.

• Net loss narrowed to €-578k from €-861k year-over-year, with EPS improving to €-0.10.

Financial highlights

• Gross profit was €14.3 million, down 1.1% year-over-year, with a lower cost of materials ratio (37.3%).

• Operating profit (EBIT) improved to €-357k from €-779k.

• Cash flow from operating activities dropped to €-217k from €1.7 million due to higher inventories and lower sales.

• Equity ratio remained strong at 51.6%.

Outlook and guidance

• Management expects FY 2024/25 sales between €95–105 million (prior year: €98.7 million).

• EBITDA is projected to be significantly higher than the prior year’s adjusted €5.5 million.

• Cost-saving and restructuring measures are expected to drive profitability.

• Positive sales and earnings growth anticipated in all business units in coming years.